↓ Skip to main content

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

Overview of attention for article published in Frontiers in oncology, August 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
Published in
Frontiers in oncology, August 2019
DOI 10.3389/fonc.2019.00701
Pubmed ID
Authors

Paul V. Viscuse, Katharine A. Price, Joaquin J. Garcia, David J. Schembri-Wismayer, Ashish V. Chintakuntlawar

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 15%
Student > Bachelor 4 15%
Other 3 12%
Student > Doctoral Student 1 4%
Student > Ph. D. Student 1 4%
Other 1 4%
Unknown 12 46%
Readers by discipline Count As %
Medicine and Dentistry 10 38%
Biochemistry, Genetics and Molecular Biology 2 8%
Neuroscience 1 4%
Nursing and Health Professions 1 4%
Unknown 12 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2022.
All research outputs
#8,540,769
of 25,385,509 outputs
Outputs from Frontiers in oncology
#3,358
of 22,432 outputs
Outputs of similar age
#143,493
of 359,095 outputs
Outputs of similar age from Frontiers in oncology
#77
of 302 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,432 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,095 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 302 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.